AIM ImmunoTech swaps $400K debt for 1.75M shares
AIM ImmunoTech converted about $400,000 of debt into 1.75 million common shares in exchanges with an existing lender.
Rhea-AI Filing Summary
AIM ImmunoTech Inc. (AIM) entered into two exchange agreements with Streeterville Capital, LLC between September 8 and September 9, 2026, using corresponding partitioned promissory notes tied to a previously issued promissory note dated November 18, 2025. Under these agreements, approximately $400,000 of debt was converted into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. Stockholders had previously approved the conversion or other satisfaction of the promissory note pursuant to NYSE American Company Guide Sections 713(a) and 713(b) at a special meeting held on July 15, 2026. The exchange shares were or will be issued in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 3.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Debt converted: $400,000
Exchange shares issued: 1,749,434 shares
Average conversion price: $0.228 per share
+2 more
5 metrics
Debt converted
$400,000
Approximate principal amount of the November 18, 2025 promissory note exchanged into equity
Exchange shares issued
1,749,434 shares
Common stock issued or to be issued to Streeterville Capital, LLC under the exchange agreements
Average conversion price
$0.228 per share
Average price at which debt was converted into AIM ImmunoTech common stock
Shareholder approval date
July 15, 2026
Special meeting where stockholders approved conversion or satisfaction of the promissory note
Number of exchange agreements
2
Total exchange agreements entered into with Streeterville Capital, LLC from September 8 to 9, 2026
Key Terms
Exchange Agreements, Partitioned Promissory Notes, Promissory Note, Section 3(a)(9), +1 more
5 terms
Exchange Agreements financial
"entered into a total of two exchange agreements (the “Exchange Agreements”)"
A contractual arrangement where two or more parties agree to swap assets, securities, or obligations under specified terms and conditions, such as share-for-share exchanges, debt-for-equity conversions, or asset swaps. These agreements matter to investors because they change who owns what and how a company’s balance sheet and future cash flows look—think of it like two people trading items that can alter each person’s overall collection and resale value.
Partitioned Promissory Notes financial
"for each, a corresponding partitioned promissory note (together, the “Partitioned Promissory Notes”)"
Promissory Note financial
"related to that certain Promissory Note dated November 18, 2025 (the “Promissory Note”)"
A promissory note is a written IOU in which one party promises to pay a specific sum, often with interest, to another party by a set date or on demand. Investors care because it functions like a loan: it creates a legal claim on future cash flows, carries credit and timing risk, and can affect valuation or liquidity—think of it as a formal, tradable promise to be repaid that can be assessed like any other debt investment.
Section 3(a)(9) regulatory
"pursuant to the exemption from the registration requirements ... provided by Section 3(a)(9)"
Section 3(a)(9) is a provision of U.S. securities law that exempts certain exchanges of an issuer’s own securities with its existing holders from the usual public registration rules, typically when the swap doesn’t involve a public offering or outside buyers. For investors, it matters because such exchanges can change who holds what, affect dilution and liquidity, and may occur with less public disclosure than a registered sale — think of it like swapping old coupons for new ones behind the scenes rather than selling them in a public marketplace.
NYSE American Company Guide Sections 713(a) and 713(b) regulatory
"pursuant to NYSE American Company Guide Sections 713(a) and 713(b)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did AIM (AIM ImmunoTech Inc.) announce in this 8-K?
AIM ImmunoTech entered into two exchange agreements with Streeterville Capital, LLC, converting a portion of an existing promissory note into shares of its common stock using corresponding partitioned promissory notes.
What was the average conversion price in AIM’s (AIM) debt-for-equity exchange?
The average conversion price in AIM ImmunoTech’s exchange with Streeterville Capital, LLC was approximately $0.228 per share for the 1,749,434 common shares issued or to be issued.
AI-generated analysis. How Rhea-AI works. Not financial advice.
